Releases

22.03.2021

VALBIOTIS obtains ISO 9001 certification for its activities in “Design, development and production control of solutions for preventing and combating metabolic and cardiovascular diseases”

Download

17.03.2021

VALBIOTIS releases its 2020 annual results

Download

11.03.2021

VALBIOTIS: 2021 financial communication calendar

Download

08.03.2021

VALBIOTIS selected to present TOTUM-854’s results on arterial hypertension at the annual meeting of the European Society of Hypertension (ESH) and the International Society of Hypertension (ISH) in April 2021

Download

22.02.2021

VALBIOTIS announces the First Patient’s First Visit in the Phase II HEART clinical study on TOTUM-070 and steps up its research program against hypercholesterolemia in 2021

Download

15.02.2021

VALBIOTIS authorized to launch HEART, the Phase II multi-center clinical study with TOTUM-070, for the reduction of blood LDL-cholesterol levels

Download

27.01.2021

Report of the liquidity contract – 2nd semester 2020 [in French]

Download

11.01.2021

VALBIOTIS announces its participation in the 39th J.P. Morgan Healthcare annual conference as well as in H.C. Wainwright BioConnect from January 11-14, 2021, in virtual format

Download

27.10.2020

VALBIOTIS presents the first market data on untreated LDL-hypercholesterolemia for TOTUM-070, and announces the initiation of the Phase II clinical study HEART

Download

05.10.2020

VALBIOTIS integrates the EnterNext PEA-PME 150 index from Euronext Paris

Download

30.09.2020

VALBIOTIS publishes its 2020 half-year results and provides an update on its global strategic partnership with Nestlé Health Science, its strong financial visibility and the promising advances in its pipeline

Download

21.09.2020

VALBIOTIS selected to present 3 studies on TOTUM-63 by the European Association for the Study of Diabetes (EASD)

Download

14.09.2020

VALBIOTIS receives US and European TOTUM-070 patent for reducing hypercholesterolemia

Download

03.08.2020

Provision of the Registration Document (R.20-018) (in French)

Download

31.07.2020

Half year report of the liquidity contract – July 2020 (in French)

Download

28.07.2020

VALBIOTIS announces a cash position of €10.9M at 30 June 2020

Download

17.07.2020

VALBIOTIS opens up its capital to a new shareholder: AMIRAL GESTION

Download

15.07.2020

VALBIOTIS announces the First Patient First Visit in the international Phase II/III REVERSE-IT clinical study on TOTUM-63 to reduce Type 2 Diabetes risk factors

Download

08.07.2020

VALBIOTIS: authorization to launch the international Phase II/III REVERSE-IT clinical study on TOTUM-63, to reduce Type 2 Diabetes risk factors

Download

12.06.2020

VALBIOTIS selected at the 80th Scientific Sessions of the American Diabetes Association to present Phase II clinical results of TOTUM-63 in prediabetes

Download

13.05.2020

21.04.2020

VALBIOTIS publishes its annual results for 2019

Download

16.04.2020

VALBIOTIS accelerates the clinical development of its pipeline in new indications: reducing cardiovascular risk and hepatic steatosis

Download

07.04.2020

VALBIOTIS announces its 2020 financial communication calendar (in French)

Download

02.04.2020

As part of a global partnership with Nestlé Health Science, VALBIOTIS initiates the pivotal late stage development phase of TOTUM-63, a plant-derived active substance with clinically demonstrated metabolic health benefits in people with prediabetes

Download

05.02.2020

Corporate Press Kit

Download

05.02.2020

VALBIOTIS announces a global strategic partnership with NESTLÉ HEALTH SCIENCE for the development and commercialization of TOTUM-63, a plant-derived active substance with clinically demonstrated metabolic health benefits on prediabetics

Download

04.02.2020

Suspension of the trading of VALBIOTIS shares on Euronext Growth (in French)

Download

31.01.2020

Half year report of the liquidity contract – January 2019 (in French)

Download

31.10.2019

VALBIOTIS announces the success of its capital increase with maintenance of the DPS for an amount of 7.2 million euros (in French)

Download

10.10.2019

VALBIOTIS launches a share capital increase with Shareholders’ Preferential Subscription Rights (in French)

Download

16.09.2019

VALBIOTIS presents positive results from a study on TOTUM-63, active substance of VALEDIA®, at EASD 2019

Download

02.09.2019

Additional positive results from the Phase IIA clinical study on VALEDIA® in lipid metabolism and arterial hypertension

Download

30.08.2019

2019 half-year report and update on key achievements (in French)

Download

01.08.2019

Provision of the Registration Document (R 19-030) and Statement of cash position as of June 30, 2019 (in French)

Download

26.07.2019

Half year report of the liquidity contract – July 2019 (in French)

Download

03.07.2019

VALBIOTIS announces positive results from the Phase IIA clinical study of VALEDIA®, now the first product proven effective in people with prediabetes

Download

24.06.2019

VALBIOTIS participates in the first HealthTech Investor Days, organized by France Biotech

Download

07.06.2019

VALBIOTIS to present novel data about TOTUM-63 and metabolic diseases prevention at the 2019 scientific sessions of the American Diabetes Association

Download

28.05.2019

VALBIOTIS succeeds in the industrial production of VALEDIA®, a major scientific innovation for prediabetic people, in collaboration with the Pierre Fabre group

Download

02.04.2019

VALBIOTIS received two public subventions for a total amount of 885 000 euros

Download

22.03.2019

VALBIOTIS presents its 2019 financial calendar

Download

19.03.2019

VALBIOTIS strengthens its Supervisory Board with the appointment of Agnès TIXIER

Download

11.03.2019

VALBIOTIS reports exclusive data on the prediabetes market: a considerable potential for VALEDIA®

Download

08.03.2019

VALBIOTIS Provides 2018 Financial Results and Corporate Update

Download

11.02.2019

VALBIOTIS obtains the European patent for VALEDIA®

Download

04.02.2019

VALBIOTIS strengthens its Board of Directors with the appointment of Murielle CAZAUBIEL

Download

30.01.2019

Update on the liquidity contract (in French)

Download

24.01.2019

VALBIOTIS appoints Josep INFESTA, international expert in Consumer Healthcare, Head of Global Business Development

Download

07.01.2019

VALBIOTIS is taking part in the 37th J.P. Morgan Healthcare conference, from 7 to 10 January 2019 in San Francisco, California

Download

28.11.2018

VALBIOTIS recognized for its IPO at the 2018 INVESTOR AWARDS

Download

12.11.2018

VALBIOTIS announces expansion of application for VALEDIA to include NASH prevention

Download

06.11.2018

VALBIOTIS confirms the publication of the results from international Phase IIA clinical study evaluating VALEDIA® for the risk reduction of type 2 diabetes, by mid-2019

Download

30.10.2018

VALBIOTIS signs scientific partnership with CarMeN, biomedical research laboratory in the field of metabolic diseases

Download

17.10.2018

VALBIOTIS confirms its interest in the study of the intestinal microbiota

Download

08.10.2018

Appointment of Murielle CAZAUBIEL as Head of Development and Medical Affairs

Download

05.10.2018

Strengthening of the liquidity contract (in French)

Download

03.10.2018

VALEDIA®: Key data supporting the submission of a health claim

Download

02.10.2018

Successful capital increase by private placement of € 2.3M (in French)

Download

01.10.2018

Launching a capital increase by private investment (in French)

Download

18.09.2018

VALBIOTIS expands its innovation capacity with its Preclinical Research platform

Download

11.09.2018

Positive results from Phase I/II clinical study on LpD64

Download

30.08.2018

Appointment of Pascal SIRVENT to the Board of Directors of VALBIOTIS

Download

17.07.2018

Half-year report of the liquidity contract – July 2018 (in French)

Download

10.07.2018

Positive results from first Phase I/II clinical study of VAL-070 in hypercholesterolemia

Download

19.06.2018

Cécile Merle appointed to the position of Quality Assurance Director

Download

07.06.2018

VALBIOTIS confirms its deployment in the United-States, to prepare the future commercialization of VALEDIA®

Download

15.05.2018

The clinical development of VALEDIA® initiated in the USA

Download

14.05.2018

Evolution in the composition of the board of Directors (in French)

Download

03.04.2018

Annual results 2017

Download

21.03.2018

Dr. Christine Roy-Duval appointed as Director of Development and Medical Affairs

Download

15.03.2018

VALBIOTIS obtains strategic patent for VALEDIA® in the United States

Download

06.03.2018

LpD64 acts on alterations of the microbiota involved in the development of obesity

Download

27.02.2018

Completion of Phase I/II clinical study recruitment for VAL-070, a product to reduce a cardiovascular risk factor

Download

23.02.2018

2018 financial communication calendar

Download

31.01.2018

Half-year report of the liquidity contract with PORTZAMPARC, with increased liquidity

Download

22.01.2018

VALBIOTIS announces a significant effect of VALEDIA® on intestinal microbiota

Download

08.01.2018

VALBIOTIS invited to participate in annual J.P. Morgan Healthcare conference

Download

06.12.2017

Positive preclinical results for the active ingredient in VAL-63-NAFLD on non-alcoholic fatty liver, a risk factor for NASH

Download

04.12.2017

Metformin + TOTUM-63 combination: first positive preclinical data for possible use in diabetes real life practice

Download

08.11.2017

VALEDIA®: launch of “pivotal” REVERSE-IT clinical trial to obtain a health claim

Download

16.10.2017

LIPIDRIVE®: efficacy confirmed in three models, finalization of recruitment for Phase I/II in humans

Download

29.09.2017

Consolidated results for the first half of 2017

Download

20.09.2017

International pharmaceutical and nutrition expert Dr. Jean Zetlaoui joins VALBIOTIS’ Supervisory Board

Download

07.09.2017

Pascal SIRVENT appointed Director of Discovery and Preclinical Research

Download

05.09.2017

VALBIOTIS opens a new Clinical Investigation Center at the Institut Pasteur in Lille as part of the Phase IIa study on TOTUM-63, the active ingredient of Valedia®

Download

09.06.2017

Results of Phase I/II clinical study on the active ingredient of Valedia®

Download

09.06.2017

VALBIOTIS will present the results of its Phase I/II clinical study on the active ingredient of Valedia®, TOTUM-63, during the 77th Scientific Sessions of the American Diabetes Association

Download

02.06.2017

VALBIOTIS Initial Public Offering records huge success

Download

24.04.2017

Sébastien PELTIER, CEO of VALBIOTIS, presents his vision of diabetes-free world at l’Echappée Volée

Download

12.04.2017

Two partnership agreements to assess the effects of TOTUM-63, the active ingredient Valedia®, on intestinal microbiota

Download

30.03.2017

VALBIOTIS at the 77th scientific sessions of the American Diabetes Association

Download

14.04.2016

Valbiotis at the American Diabetes Congress thanks to its prevention solution

Download

29.01.2016

VALBIOTIS opens a new location in Clermont Ferrand

Download

02.07.2015

VALBIOTIS, winner of I-Lab

Download

22.01.2015

Science at the service of dietary supplements

Download